SIRT3 inhibits prostate cancer by destabilizing oncoprotein c-MYC through regulation of the PI3K/Akt pathway

Oncotarget

Volumn 6, Issue 28, 2015, Pages 26494-26507

  Quan, Yizhou ^a   Wang, Naitao ^a   Chen, Qianqian ^a   Xu, Jin ^a   Cheng, Wei ^b   Di, Meijuan ^b   Xia, Weiliang ^a   Gao, Wei Qiang ^a,c  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^c Collaborative Innovation Center of Systems Biomedicine ^*  (China)

Author keywords

c MYC; Oncoprotein; PI3K Akt pathway; Prostate cancer; SIRT3

Indexed keywords

LENTIVIRUS VECTOR; MESSENGER RNA; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SIRTUIN 3; MYC PROTEIN, HUMAN; SIRT3 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; UBIQUITINATION; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RNA INTERFERENCE; TIME FACTOR; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICE, INBRED BALB C; MICE, NUDE; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN STABILITY; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MYC; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SIRTUIN 3; TIME FACTORS; TRANSFECTION; UBIQUITINATION;

EID: 84944457493     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4764     Document Type: Article

References (49)

1. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA: a Cancer Journal for Clinicians. 2014; 64:9-29.
2. Chen W, Zheng R, Zeng H, Zhang S and He J. Annual report on status of cancer in China, 2011. Chinese Journal of Cancer Research. 2015; 27:2-12.
3. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD and Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999; 281:1591-1597.
4. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr., Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D and Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. The New England Journal of Medicine. 2004; 351:1513-1520.
5. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M and Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. Journal of Clinical Oncology. 2008; 26:242-245.
6. Hartwell HJ, Petrosky KY, Fox JG, Horseman ND and Rogers AB. Prolactin prevents hepatocellular carcinoma by restricting innate immune activation of c-Myc in mice. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111:11455-11460.
7. Delpuech O, Griffiths B, East P, Essafi A, Lam EW, Burgering B, Downward J and Schulze A. Induction of Mxi1-SR alpha by FOXO3a contributes to repression of Myc-dependent gene expression. Molecular and Cellular Biology. 2007; 27:4917-4930.
8. Mahoney S, Arfuso F, Millward M and Dharmarajan A. The effects of phenoxodiol on the cell cycle of prostate cancer cell lines. Cancer Cell International. 2014; 14:110.
9. Brown K, Xie S, Qiu X, Mohrin M, Shin J, Liu Y, Zhang D, Scadden DT and Chen D. SIRT3 reverses aging-associated degeneration. Cell Reports. 2013; 3:319-327.
10. Chandel NS and Tuveson DA. The promise and perils of antioxidants for cancer patients. The New England Journal of Medicine. 2014; 371:177-178.
11. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, Kalyanaraman B, Mutlu GM, Budinger GR and Chandel NS. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107:8788-8793.
12. Kim HS, Patel K, Muldoon-Jacobs K, Bisht KS, Aykin-Burns N, Pennington JD, van der Meer R, Nguyen P, Savage J, Owens KM, Vassilopoulos A, Ozden O, Park SH, Singh KK, Abdulkadir SA, Spitz DR, et al. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell. 2010; 17:41-52.
13. Finley LW, Carracedo A, Lee J, Souza A, Egia A, Zhang J, Teruya-Feldstein J, Moreira PI, Cardoso SM, Clish CB, Pandolfi PP and Haigis MC. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1alpha destabilization. Cancer Cell. 2011; 19:416-428.
14. Memarzadeh S, Zong Y, Janzen DM, Goldstein AS, Cheng D, Kurita T, Schafenacker AM, Huang J and Witte ON. Cell-autonomous activation of the PI3-kinase pathway initiates endometrial cancer from adult uterine epithelium. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107:17298-17303.
15. Memarzadeh S, Cai H, Janzen DM, Xin L, Lukacs R, Riedinger M, Zong Y, DeGendt K, Verhoeven G, Huang J and Witte ON. Role of autonomous androgen receptor signaling in prostate cancer initiation is dichotomous and depends on the oncogenic signal. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108:7962-7967.
16. Dominguez-Caceres MA, Garcia-Martinez JM, Calcabrini A, Gonzalez L, Porque PG, Leon J and Martin-Perez J. Prolactin induces c-Myc expression and cell survival through activation of Src/Akt pathway in lymphoid cells. Oncogene. 2004; 23:7378-7390.
17. Riquelme E, Suraokar MB, Rodriguez J, Mino B, Lin HY, Rice DC, Tsao A and Wistuba, II. Frequent Coamplification and Cooperation between C-MYC and PVT1 Oncogenes Promote Malignant Pleural Mesothelioma. Journal of Thoracic Oncology. 2014; 9:998-1007.
18. Little CD, Nau MM, Carney DN, Gazdar AF and Minna JD. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature. 1983; 306:194-196.
19. Li L, Ren C, Yang G, Fattah EA, Goltsov AA, Kim SM, Lee JS, Park S, Demayo FJ, Ittmann MM, Troncoso P and Thompson TC. GLIPR1 suppresses prostate cancer development through targeted oncoprotein destruction. Cancer Research. 2011; 71:7694-7704.
20. Buttyan R, Sawczuk IS, Benson MC, Siegal JD and Olsson CA. Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers. The Prostate. 1987; 11:327-337.
21. Jenkins RB, Qian J, Lieber MM and Bostwick DG. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Research. 1997; 57:524-531.
22. Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, Hahn WC, Stukenberg PT, Shenolikar S, Uchida T, Counter CM, Nevins JR, Means AR and Sears R. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nature Cell Biology. 2004; 6:308-318.
23. Salghetti SE, Kim SY and Tansey WP. Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc. The EMBO journal. 1999; 18:717-726.
24. Gregory MA and Hann SR. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Molecular and Cellular Biology. 2000; 20:2423-2435.
25. Welcker M, Orian A, Jin J, Grim JE, Harper JW, Eisenman RN and Clurman BE. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101:9085-9090.
26. Graff JR, Konicek BW, McNulty AM, Wang Z, Houck K, Allen S, Paul JD, Hbaiu A, Goode RG, Sandusky GE, Vessella RL and Neubauer BL. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. The Journal of Biological Bhemistry. 2000; 275:24500-24505.
27. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C and Abate-Shen C. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. The Journal of Clinical Investigation. 2008; 118:3051-3064.
28. Majumder PK and Sellers WR. Akt-regulated pathways in prostate cancer. Oncogene. 2005; 24:7465-7474.
29. Tommasi S, Zheng A, Yoon JI and Besaratinia A. Epigenetic targeting of the Nanog pathway and signaling networks during chemical carcinogenesis. Carcinogenesis. 2014; 35:1726-1736.
30. Fang L, Zhang L, Wei W, Jin X, Wang P, Tong Y, Li J, Du JX and Wong J. A methylation-phosphorylation switch determines Sox2 stability and function in ESC maintenance or differentiation. Molecular Cell. 2014; 55:537-551.
31. Lin Y, Yang Y, Li W, Chen Q, Li J, Pan X, Zhou L, Liu C, Chen C, He J, Cao H, Yao H, Zheng L, Xu X, Xia Z, Ren J, et al. Reciprocal regulation of Akt and Oct4 promotes the self-renewal and survival of embryonal carcinoma cells. Molecular Cell. 2012; 48:627-640.
32. Pillai VB, Sundaresan NR, Kim G, Gupta M, Rajamohan SB, Pillai JB, Samant S, Ravindra PV, Isbatan A and Gupta MP. Exogenous NAD blocks cardiac hypertrophic response via activation of the SIRT3-LKB1-AMP-activated kinase pathway. The Journal of Biological Chemistry. 2010; 285:3133-3144.
33. Pillai VB, Sundaresan NR and Gupta MP. Regulation of Akt signaling by sirtuins: its implication in cardiac hypertrophy and aging. Circulation Research. 2014; 114:368-378.
34. Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, Castillo-Martin M, Quinn SA, Rodriguez-Barrueco R, Bonal DM, Charytonowicz E, Gladoun N, de la Iglesia-Vicente J, Petrylak DP, Benson MC, Silva JM and Cordon- Cardo C. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehogdependent tumor-initiating cells. Cancer Cell. 2012; 22:373- 388.
35. Sviripa VM, Zhang W, Kril LM, Liu AX, Yuan Y, Zhan CG, Liu C and Watt DS. Halogenated diarylacetylenes repress c-myc expression in cancer cells. Bioorganic & Medicinal Chemistry Letters. 2014; 24:3638-3640.
36. Behera B, Mishra D, Roy B, Devi KS, Narayan R, Das J, Ghosh SK and Maiti TK. Abrus precatorius Agglutinin- Derived Peptides Induce ROS-Dependent Mitochondrial Apoptosis through JNK and Akt/P38/P53 Pathways in HeLa Cells. Chemico-Biological Interactions. 2014.
37. Ahn BH, Kim HS, Song S, Lee IH, Liu J, Vassilopoulos A, Deng CX and Finkel T. A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105:14447-14452.
38. Qiu X, Brown K, Hirschey MD, Verdin E and Chen D. Calorie restriction reduces oxidative stress by SIRT3- mediated SOD2 activation. Cell Metabolism. 2010; 12:662- 667.
39. Shi T, Wang F, Stieren E and Tong Q. SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. The Journal of Biological Chemistry. 2005; 280:13560-13567.
40. Haigis MC, Deng CX, Finley LW, Kim HS and Gius D. SIRT3 is a mitochondrial tumor suppressor: a scientific tale that connects aberrant cellular ROS, the Warburg effect, and carcinogenesis. Cancer Research. 2012; 72:2468-2472.
41. Akinyeke T, Matsumura S, Wang X, Wu Y, Schalfer ED, Saxena A, Yan W, Logan SK and Li X. Metformin targets c-MYC oncogene to prevent prostate cancer. Carcinogenesis. 2013; 34:2823-2832.
42. Janghorban M, Farrell AS, Allen-Petersen BL, Pelz C, Daniel CJ, Oddo J, Langer EM, Christensen DJ and Sears RC. Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 2014.
43. Ramsay G, Evan GI and Bishop JM. The protein encoded by the human proto-oncogene c-myc. Proceedings of the National Academy of Sciences of the United States of America. 1984; 81:7742-7746.
44. Roth M and Chen WY. Sorting out functions of sirtuins in cancer. Oncogene. 2014; 33:1609-1620.
45. Xue L, Xu F, Meng L, Wei S, Wang J, Hao P, Bian Y, Zhang Y and Chen Y. Acetylation-dependent regulation of mitochondrial ALDH2 activation by SIRT3 mediates acute ethanol-induced eNOS activation. FEBS Letters. 2012; 586:137-142.
46. Quan Y, Xia L, Shao J, Yin S, Cheng CY, Xia W and Gao WQ. Adjudin protects rodent cochlear hair cells against gentamicin ototoxicity via the SIRT3-ROS pathway. Scientific Reports. 2015; 5:8181.
47. Xie QR, Liu Y, Shao J, Yang J, Liu T, Zhang T, Wang B, Mruk DD, Silvestrini B, Cheng CY and Xia W. Male contraceptive Adjudin is a potential anti-cancer drug. Biochemical Pharmacology. 2013; 85:345-355.
48. Shao J, Liu T, Xie QR, Zhang T, Yu H, Wang B, Ying W, Mruk DD, Silvestrini B, Cheng CY and Xia W. Adjudin attenuates lipopolysaccharide (LPS)- and ischemia-induced microglial activation. Journal of Neuroimmunology. 2013; 254:83-90.
49. Liu T, Zhang T, Yu H, Shen H and Xia W. Adjudin protects against cerebral ischemia reperfusion injury by inhibition of neuroinflammation and blood-brain barrier disruption. Journal of Neuroinflammation. 2014; 11:107.